A federal jury in Delaware has ordered a unit of Takeda Pharmaceutical Co. to pay Bayer HealthCare LLC $155 million in damages for infringing a patent related to Bayer’s hemophilia treatment.

According to court records posted Tuesday, the Wilmington jury rejected Baxalta’s arguments that Bayer’s patent was invalid after six days of trial in the case, which was filed in December 2016, when Baxalta was still owned by Irish biopharmacuetical firm Shire. The jury applied a 17.7 percent royalty rate to a base of nearly $873 million to reach its total damage award.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]